---
title: "Kira Sheinerman Secures Board Rights at Niki BioSolutions with 51.56% Stake"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293795714.md"
description: "Kira S. Sheinerman acquired a 51.56% stake in Niki BioSolutions (Nasdaq: NIKI) via its July 20, 2026 merger with Aptorum. Under a Stockholders Agreement, she holds significant governance rights, including the ability to designate two board nominees while owning at least 36% and one nominee at 25%. Major corporate actions require her written consent while she holds at least 25%, and share transfers are restricted for six months."
datetime: "2026-07-24T20:36:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293795714.md)
  - [en](https://longbridge.com/en/news/293795714.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293795714.md)
generator: "portal-rs"
---

# Kira Sheinerman Secures Board Rights at Niki BioSolutions with 51.56% Stake

Kira S. Sheinerman disclosed beneficial ownership of 51.56% of Niki BioSolutions, Inc.’s common stock. The stake resulted from the July 20, 2026 merger in which Aptorum domesticated and renamed itself Niki BioSolutions, with shares issued as non-cash consideration. The position gives Sheinerman significant governance rights and influence at the newly listed Nasdaq company.

**Investor Intent**

Sheinerman received the shares solely as merger consideration and entered into a Stockholders Agreement with Niki BioSolutions. Under this agreement, she “may designate two nominees” to the board while she owns at least 36% of the stock, and one nominee while she owns at least 25%, and she will vote with the board’s nominating committee for other directors until the 2027 annual meeting.

While she holds at least 25%, certain major corporate actions “require the prior written consent” of Sheinerman. The agreement also restricts transfers of the covered shares for six months after it took effect.

**Investor's Background**

Kira S. Sheinerman is a U.S. biotech executive and a co-founder of DiamiR Biosciences, where she focused on diagnostics for neurodegenerative diseases. She serves as a director of Niki BioSolutions, Inc. following the merger. Her investment approach centers on building and guiding early-stage life sciences companies through key strategic milestones.

Original SEC Filing: Niki BioSolutions, Inc. \[ NIKI \] - SCHEDULE 13D - Jul. 24, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [NIKI.US](https://longbridge.com/en/quote/NIKI.US.md)
- [APM.US](https://longbridge.com/en/quote/APM.US.md)

## Related News & Research

- [Niki BioSolutions weighs financing options as going-concern warning clouds post-merger outlook](https://longbridge.com/en/news/296654125.md)
- [Aptorum files amended 8-K updating DiamiR Biosciences financial statements](https://longbridge.com/en/news/296654284.md)
- [Aptorum Group GAAP EPS of -$1.60](https://longbridge.com/en/news/296654186.md)
- [Aptorum FY26 H1 net loss widens to $1.31 million; operating cash outflow rises to $1.55 million](https://longbridge.com/en/news/296653498.md)
- [B3 Consulting Group shareholders approved Habberstad stake sale to HAS Gruppen for NOK 15.9 million](https://longbridge.com/en/news/296357057.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**